Cargando…

Addition of Multimodal Immunotherapy to Combination Treatment Strategies for Children with DIPG: A Single Institution Experience

Background: The prognosis of children with diffuse intrinsic pontine glioma (DIPG) remains dismal despite radio- and chemotherapy or molecular-targeted therapy. Immunotherapy is a powerful and promising approach for improving the overall survival (OS) of children with DIPG. Methods: A retrospective...

Descripción completa

Detalles Bibliográficos
Autores principales:	Van Gool, Stefaan W., Makalowski, Jennifer, Bonner, Erin R., Feyen, Oliver, Domogalla, Matthias P., Prix, Lothar, Schirrmacher, Volker, Nazarian, Javad, Stuecker, Wilfried
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2020
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7281768/ https://www.ncbi.nlm.nih.gov/pubmed/32438648 http://dx.doi.org/10.3390/medicines7050029

Ejemplares similares

DIPG-38. ADDITION OF MULTIMODAL IMMUNOTHERAPY TO COMBINATION TREATMENT STRATEGIES FOR CHILDREN WITH DIPG: FINAL RESULTS OF A COHORT OF CHILDREN
por: Van Gool, Stefaan, et al.
Publicado: (2020)

Randomized Controlled Immunotherapy Clinical Trials for GBM Challenged
por: Van Gool, Stefaan W., et al.
Publicado: (2020)

Individualized Multimodal Immunotherapy for Adults with IDH1 Wild-Type GBM: A Single Institute Experience
por: Van Gool, Stefaan W., et al.
Publicado: (2023)

Synergy between TMZ and individualized multimodal immunotherapy to improve overall survival of IDH1 wild-type MGMT promoter-unmethylated GBM patients
por: Van Gool, Stefaan W., et al.
Publicado: (2022)

Counteracting Immunosuppression in the Tumor Microenvironment by Oncolytic Newcastle Disease Virus and Cellular Immunotherapy
por: Schirrmacher, Volker, et al.
Publicado: (2022)

Breaking Therapy Resistance: An Update on Oncolytic Newcastle Disease Virus for Improvements of Cancer Therapy
por: Schirrmacher, Volker, et al.
Publicado: (2019)

Evidence-Based Medicine in Oncology: Commercial Versus Patient Benefit
por: Schirrmacher, Volker, et al.
Publicado: (2020)

Dendritic cell vaccination for glioblastoma multiforme patients: has a new milestone been reached?
por: Van Gool, Stefaan W., et al.
Publicado: (2023)

The Application of Evidence-Based Medicine in Individualized Medicine
por: Van de Vliet, Peter, et al.
Publicado: (2023)

DIPG-48. MRI volumetric and machine learning based analyses predict survival outcome in pediatric diffuse midline glioma
por: Bonner, Erin R, et al.
Publicado: (2022)

Past, present and future of Focused Ultrasound as an adjunct or complement to DIPG/DMG therapy: A consensus of the 2021 FUSF DIPG meeting
por: Parekh, Kavya, et al.
Publicado: (2023)

DIPG-20. DETERMINATION AND MANAGEMENT OF HYDROCEPHALUS IN PATIENTS WITH DIPG, AN INSTITUTIONAL EXPERIENCE
por: Fonseca, Adriana, et al.
Publicado: (2020)

IMMU-02. CMV-EXPANDED T-CELLS IN GLIOBLASTOMA PATIENTS: TRANSLATIONAL RESEARCH
por: Kampers, Linde F C, et al.
Publicado: (2023)

DIPG-18. AI HUNTING FOR NEW DRUGS IN PEDIATRIC GLIOMA
por: Hashizume, Rintaro, et al.
Publicado: (2023)

DIPG-23. THE ROLE OF FOXO3 IN DMG RESISTANCE AND RESPONSE TO THERAPIES TARGETING DMG METABOLISM
por: Petrovic, Antonela, et al.
Publicado: (2023)

DIPG-42. TOWARD MULTIMODALITY THERAPY FOR DIPG/DMG: DEVELOPMENT AND INVESTIGATION OF CRANIOSPINAL IRRADIATION AND CONVECTION-ENHANCED DELIVERY PDX MODELS
por: Knox, Aaron J, et al.
Publicado: (2020)

DIPG-39. NOVEL PROTEOMIC ANALYSIS REVEALS EPIGENETIC THERAPEUTIC TARGETS IN PEDIATRIC GLIOMA
por: Li, Daphne, et al.
Publicado: (2020)

A standardized autopsy procurement allows for the comprehensive study of DIPG biology
por: Kambhampati, Madhuri, et al.
Publicado: (2015)

DIPG-74. RE-IRRADIATION OF DIPG: DATA FROM THE INTERNATIONAL DIPG REGISTRY
por: Lafay-Cousin, Lucie, et al.
Publicado: (2020)

DIPG-22. TRIPTOLIDE AS A POTENTIALLY PROMISING THERAPY FOR DIFFUSE MIDLINE GLIOMA
por: Ciani, Ludovica, et al.
Publicado: (2023)

DIPG-48. DIPG THROUGH THE LOOKING GLASS
por: Senga, Sasi S
Publicado: (2023)

EPCT-12. PNOC015: PHASE 1 STUDY OF MTX110 (AQUEOUS PANOBINOSTAT) DELIVERED BY CONVECTION ENHANCED DELIVERY (CED) IN CHILDREN WITH NEWLY DIAGNOSED DIFFUSE INTRINSIC PONTINE GLIOMA (DIPG) PREVIOUSLY TREATED WITH RADIATION THERAPY
por: Mueller, Sabine, et al.
Publicado: (2020)

DIPG-51. ACVR1 MUTATIONS PROMOTE TUMOR GROWTH IN MODELS OF DIFFUSE INTRINSIC PONTINE GLIOMA
por: Adorno, Jennifer Ocasio, et al.
Publicado: (2020)

DIPG-16. Evaluation of myeloid component of DIPG microenvironment
por: Mishra, Deepak, et al.
Publicado: (2022)

DIPG-03. Therapeutic targeting of purine biosynthesis in DIPG
por: Mersich, Ian, et al.
Publicado: (2022)

DIPG-47. TSO500ctDNA sequencing reveals oncogenic mutations and copy number variations in the liquid biome of children with diffuse midline glioma
por: Bonner, Erin R, et al.
Publicado: (2022)

DIPG-03. IDENTIFICATION OF NEW THERAPEUTIC TARGETS BY ARRAYED CRISPRA-BASED APPROACH TO MAP RADIORESISTANCE IN DMG
por: Fernandez, Solène, et al.
Publicado: (2023)

Brain Tumor Immunotherapy: What have We Learned so Far?
por: Van Gool, Stefaan Willy
Publicado: (2015)

DIPG-46. NON-DIPG PATIENTS ENROLLED IN THE INTERNATIONAL DIPG REGISTRY: HISTOPATHOLOGIC EVALUATION OF CENTRAL NEURO-IMAGING REVIEW
por: Lazow, Margot A, et al.
Publicado: (2020)

Neuroblastoma and DIPG Organoid Coculture System for Personalized Assessment of Novel Anticancer Immunotherapies
por: M. Kholosy, Waleed, et al.
Publicado: (2021)

DIPG-70. DISORDERED DNA METHYLATION IN DIPG UNDERLIES PHENOTYPIC PLASTICITY
por: Koldobskiy, Michael, et al.
Publicado: (2020)

DIPG-59. UPREGULATION OF PRENATAL PONTINE ID1 SIGNALING IN DIPG
por: Harris, Micah K, et al.
Publicado: (2020)

DIPG-57. TRANSCRIPTOMIC AND PROTEOMIC ANALYSES OF DIPG RESPONSE TO ONC201
por: Sridharan, Sreepradha, et al.
Publicado: (2020)

DIPG-12. TARGETING EPIGENETIC MODIFIERS TO INDUCE IMMUNE SIGNALING IN DIPG
por: Tetens, Ashley, et al.
Publicado: (2020)

DIPG-52. Activators of the integrated stress response synergize to kill DIPG
por: Novak, Orlandi, et al.
Publicado: (2022)

Multimodal Cancer Therapy Involving Oncolytic Newcastle Disease Virus, Autologous Immune Cells, and Bi-Specific Antibodies
por: Schirrmacher, Volker, et al.
Publicado: (2014)

Dendritic cell-based immunotherapy in ovarian cancer
por: Coosemans, An, et al.
Publicado: (2013)

DIPG-25. MAPPING TUMOR MICROENVIRONMENT USING EMERGING TECHNOLOGIES FOR PEDIATRIC BRAIN CANCERS
por: Laternser, Sandra, et al.
Publicado: (2023)

DIPG-23. SINGLE CASE REPORT OF LOW DOSE RADIOTHERAPY AND CHEMOTHERAPY IN THE TREATMENT OF DIPG
por: Tseng, Chen Kan, et al.
Publicado: (2020)

DIPG-40. TARGETING MASTER REGULATOR DEPENDENCIES IN DIFFUSE INTRINSIC PONTINE GLIOMA (DIPG)
por: Pavisic, Jovana, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_m3pduns7kd42qf4qqadhj2sbbi